<DOC>
	<DOCNO>NCT01141153</DOCNO>
	<brief_summary>Objective : The main objective evaluate pattern dual antiplatelet therapy ( aspirin , 300 mg / day + clopidogrel 75 mg / day ) compare use triple regimen ( Acenocoumarol control + acetylsalicylic acid 100 mg / day + Clopidogrel 75 mg / day ) patient atrial fibrillation , low-moderate risk stroke ( CHADS ≤ 2 ) undergo PCI-S. Design : Randomized , parallel , two arm , blind evaluation third party . Patients : 304 patient undergoing PCI-S atrial fibrillation , low-moderate risk stroke ( CHADS ≤ 2 ) , require prevention thrombosis</brief_summary>
	<brief_title>Anticoagulation Stent Intervention</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Acenocoumarol</mesh_term>
	<criteria>Patients sex old 18 year . Patients permanent atrial fibrillation , persistent paroxysmal ( least one episode ) , document electrocardiographically receive oral anticoagulation . Patients acute coronary syndrome stable angina undergoing PCIS . Patients previously give informed consent participation study . Patients follow research team 12 month provide monitoring . Patients renal failure serum creatinine 2 mg • dL1 , neurological deficit , active ulcer epigastric pain . Patients continue regular treatment NSAIDs analgesic corticosteroid . Patients undergoing reoperation . Patients study period , receive , accord medical criterion , adjuvant drug treatment specify protocol . Pregnant woman . Use investigational agent register within 30 day entry study . Patients history allergy study drug excipients . Patients severe valve disease . Patients CHADS &gt; 2 . Patients use study drug orally .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>atrial fibrillation</keyword>
	<keyword>Coronary Stent implantation</keyword>
	<keyword>Low-moderate risk stroke</keyword>
	<keyword>dual antiplatelet therapy</keyword>
	<keyword>anticoagulation</keyword>
</DOC>